Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Although the main focus of immuno-oncology has been manipulating the adaptive immune system, harnessing both the innate and adaptive arms of the immune system might produce superior tumour reduction and elimination. Tumour-associated macrophages often have net pro-tumour effects, but their embedded location and their untapped potential provide impetus to discover strategies to turn them against tumours. Strategies that deplete (anti-CSF-1 antibodies and CSF-1R inhibition) or stimulate (agonistic anti-CD40 or inhibitory anti-CD47 antibodies) tumour-associated macrophages have had some success. We hypothesized that pharmacologic modulation of macrophage phenotype could produce an anti-tumour effect. We previously reported that a first-in-class selective class IIa histone deacetylase (HDAC) inhibitor, TMP195, influenced human monocyte responses to the colony-stimulating factors CSF-1 and CSF-2 in vitro. Here, we utilize a macrophage-dependent autochthonous mouse model of breast cancer to demonstrate that in vivo TMP195 treatment alters the tumour microenvironment and reduces tumour burden and pulmonary metastases by modulating macrophage phenotypes. TMP195 induces the recruitment and differentiation of highly phagocytic and stimulatory macrophages within tumours. Furthermore, combining TMP195 with chemotherapy regimens or T-cell checkpoint blockade in this model significantly enhances the durability of tumour reduction. These data introduce class IIa HDAC inhibition as a means to harness the anti-tumour potential of macrophages to enhance cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Histone deacetylase inhibitor, TMP195, polarizes TAMs toward an anti‐tumor phenotype and increases the efficacy of carboplatin, paclitaxel, and anti‐PD‐1 therapies [84].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [84]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NIH Image to ImageJ: 25 years of image analysis
Schneider, C. A., Rasband, W. S., & Eliceiri, K. W. (2012) · Nature Methods · doi:10.1038/nmeth.2089 · Cited by 64,638
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
Hanahan, D., & Folkman, J. (1996) · Cell · doi:10.1016/s0092-8674(00)80108-7 · Cited by 6,885
Macrophage Diversity Enhances Tumor Progression and Metastasis
Qian, B.-Z., & Pollard, J. W. (2010) · Cell · doi:10.1016/j.cell.2010.03.014 · Cited by 5,188
Tumour-educated macrophages promote tumour progression and metastasis
Pollard, J. W. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1256 · Cited by 3,367
CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis
Qian, B.-Z., Li, J., Zhang, H., Kitamura, T., Zhang, J., Campion, L. R., Kaiser, E. A., Snyder, L. A., & Pollard, J. W. (2011) · Nature · doi:10.1038/nature10138 · Cited by 2,874
CSF-1R inhibition alters macrophage polarization and blocks glioma progression
Pyonteck, S. M., Akkari, L., Schuhmacher, A. J., Bowman, R. L., Sevenich, L., Quail, D. F., Olson, O. C., Quick, M. L., Huse, J. T., Teijeiro, V., et al. (2013) · Nature Medicine · doi:10.1038/nm.3337 · Cited by 2,463
High Interstitial Fluid Pressure - an Obstacle in Cancer Therapy
Heldin, C.-H., Rubin, K., Pietras, K., & Östman, A. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1456 · Cited by 2,222
Drug Resistance and the Solid Tumor Microenvironment
Tredan, O., Galmarini, C. M., Patel, K., & Tannock, I. F. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm135 · Cited by 2,116
The Immunological Genome Project: networks of gene expression in immune cells
The Immunological Genome Project Consortium, Heng, T. S. P., Painter, M. W., Elpek, K., Lukacs-Kornek, V., Mauermann, N., Turley, S. J., Koller, D., Kim, F. S., Wagers, A. J., et al. (2008) · Nature Immunology · doi:10.1038/ni1008-1091 · Cited by 1,864
Self-citation
Research works printed but not linked: 2
- DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, Gallagher WM, Wadhwani N, Keil SD, Junaid SA, Rugo HS, Hwang ES, Jirström K, West BL & Coussens LM Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy. Cancer Discovery 1, 54– 67, 10.1158/2159-8274.cd-10-0028 (2011). 22039576 PMC3203524 · DOI · Paper page
- Malhotra D, Fletcher AL, Astarita J, Lukacs-Kornek V, Tayalia P, Gonzalez SF, Elpek KG, Chang SK, Knoblich K, Hemler ME, Brenner MB, Carroll MC, Mooney DJ, Turley SJ & Immunological Genome Project C Transcriptional profiling of stroma from inflamed and resting lymph nodes defines immunological hallmarks. Nature immunology 13, 499– 510, 10.1038/ni.2262 (2012). 22466668 PMC3366863 · DOI · Paper page
Cited by
Items 201–300 of 568
Anti-Tumor Strategies by Harnessing the Phagocytosis of Macrophages
Li, S., Guo, Y.-L., Tian, J.-W., Zhang, H., Li, R., Gong, P., & Yu, Z. (2023) · Cancers · doi:10.3390/cancers15102717 · Cited by 51
“HDAC inhibitor HDAC Tumor cells / Modulate macrophage phenotypes [84]”
BackgroundProgress in targeting tumor-associated macrophages in cancer immunotherapy
Xia, W., Zhang, X., Wang, Y., Huang, Z., Guo, X., & Fang, L. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1658795 · Cited by 58
“In murine breast cancer models, TMP195 also enhanced tumor killing when combined with chemotherapy or checkpoint inhibitors (89).”
Tajaldini, M., Saeedi, M., Amiriani, T., Amiriani, A., Sedighi, S., Zadeh, F. M., Dehghan, M. H., Jahanshahi, M., Zanjan, M. G., Khalili, P., et al. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175087 · Cited by 51
Ali, M. K., Shahin, S. M., Sabri, N. A., Al-Hendy, A. A., & Yang, Q. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz227 · Cited by 46
Development of Immunotherapy Strategies Targeting Tumor Microenvironment Is Fiercely Ongoing
Bai, R., & Cui, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.890166 · Cited by 52
TMP195 Exerts Antitumor Effects on Colorectal Cancer by Promoting M1 Macrophages Polarization
Han, Y., Sun, J., Yang, Y., Liu, Y., Lou, J., Pan, H., Yao, J., & Han, W. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.73264 · Cited by 47
“TMP195 is a selective class IIa HDAC (HDAC4, -5, -7, and -9) inhibitor that has been reported to reprogram tumor-associated macrophages into tumoricidal cells and reduce tumor burden in breast cancer [21].”
BackgroundResultInfluentialTAM-targeted reeducation for enhanced cancer immunotherapy: Mechanism and recent progress
Shen, X., Zhou, S., Yang, Y., Tu, H., Xiang, Z., Zhao, J., Zhu, C., Zeng, L., & Zhang, L. L. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1034842 · Cited by 47
“In addition, explicit inhibition of monocyte responses to M-CSF and GM-CSF by class IIa HDAC inhibitor may also illustrate the promotional effect of HDAC on CSF1-CSF1R pathway, which provides an alternative way to regulate signaling pathways for macrophage polarization (81, 82).”
BackgroundImmunotherapy for Breast Cancer: Current and Future Strategies
Williams, A. D., Payne, K. K., Posey, A. D., Hill, C., Conejo-Garcia, J. R., June, C. H., & Tchou, J. C. (2017) · Current Surgery Reports · doi:10.1007/s40137-017-0194-1 · Cited by 48
“For instance, combining class IIa histone deacetylase (HDAC) inhibition with T cell checkpoint blockade enhances the durability of tumor reduction by modulating macrophage phenotypes [58].”
Nishimori, S., O’Meara, M. J., Castro, C. D., Noda, H., Çetinbaş, M., Martins, J. D. S., Ayturk, U. M., Brooks, D. J., Bruce, M., Nagata, M., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci130126 · Cited by 44
“from Immunotopics (60-2305), phosphate from BioVision (K410-”
BackgroundInfluentialReprogramming Immune Cells for Enhanced Cancer Immunotherapy: Targets and Strategies
Dong, Y., Wan, Z., Gao, X., Yang, G., & Liu, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.609762 · Cited by 47
“Inhibitors of histone deacetylase (HDACs) can repolarize the phenotype of TAMs and alter CCL1 expression in monocytes (116).”
BackgroundTsai, C.-Y., Ko, H.-J., Chiou, S.-J., Lai, Y.-L., Hou, C.-C., Javaria, T., Huang, Z.-Y., Cheng, T.-S., Hsu, T., Chuang, J., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115907 · Cited by 43
“Abnormal HDAC overexpression is observed in many tumors, such as colorectal cancer [12], breast cancer [13], and leukemia [14].”
BackgroundLeveraging microenvironmental synthetic lethalities to treat cancer
Metcalf, K. J., Alazzeh, A., Werb, Z., & Weaver, V. M. (2021) · Journal of Clinical Investigation · doi:10.1172/jci143765 · Cited by 42
“Selective modification of monocyte gene expression using the class IIa histone deacetylase (HDAC) inhibitor TMP195 polarizes TAMs to a phagocytic antitumor phenotype that enhances efficacy of carboplatin, paclitaxel, and anti–PD-1 therapies (122).”
MethodMacrophages: Targets for next-generation cancer immunotherapy
Sun, X., Park, M. D., Mérad, M., & Brown, B. D. (2026) · Cancer Cell · doi:10.1016/j.ccell.2026.01.020 · Cited by 56
HDAC7 Activates IKK/NF-κB Signaling to Regulate Astrocyte-Mediated Inflammation
Ye, J., Zhong, S., Deng, Y., Yao, X., Liu, Q., Wang, J., & Xiao, S. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-02965-6 · Cited by 41
“For instances, in a macrophage-dependent autochthonous breast cancer mouse model, application of a selective class IIa HDAC inhibitor, TMP195, can induce the recruitment and differentiation of highly phagocytic and stimulatory macrophages within tumors [15].”
Zhang, P., Du, Y., Bai, H., Wang, Z., Duan, J., Wang, X., Zhong, J. Y., Wan, R., Xu, J., He, X., et al. (2022) · BMC Medicine · doi:10.1186/s12916-022-02598-5 · Cited by 43
“Furthermore, TMP195 induced the recruitment and differentiation of highly phagocytic and stimulatory macrophages within tumors [52].”
BackgroundLi, Y., He, P., Liu, Y., Qi, M., & Dong, W. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.708093 · Cited by 41
Pramanik, S. D., Halder, A. K., Mukherjee, U., Kumar, D., Dey, Y. N., & Mogana, R. (2022) · Frontiers in Chemistry · doi:10.3389/fchem.2022.948217 · Cited by 47
“HDACi can considerably reduce cancer burden by attenuating tumor growth and regulating aberrantly proliferating vasculature (Guerriero et al., 2017).”
BackgroundMacrophage-Based Combination Therapies as a New Strategy for Cancer Immunotherapy
Tian, L., Lei, A., Tan, T., Zhu, M., Zhang, L., Mou, H., & Zhang, J. (2021) · Kidney Diseases · doi:10.1159/000518664 · Cited by 42
Differential molecular mechanistic behavior of HDACs in cancer progression
Singh, T., Kaur, P., Singh, P., Singh, S., & Munshi, A. (2022) · Medical Oncology · doi:10.1007/s12032-022-01770-4 · Cited by 46
“Class IIa HDACs inhibition promotes effector and immunomodulatory functions of macrophage to activate CD8+ cells against tumor cells which decrease tumor burden [80].”
BackgroundNew insights into the role of macrophages in cancer immunotherapy
Li, Z., Zhao, T., Zhang, R., Chen, C., & Li, J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1381225 · Cited by 51
“In the breast cancer model, the selective class-IIa HDAC inhibitor induces the anti-tumor macrophage phenotype, promotes the T-cell immune response, and increases the response to chemotherapy and immune checkpoint inhibitors (62).”
BackgroundQiu, W., Wang, B., Gao, Y., Tian, Y., Tian, M., Chen, Y., Xu, L. M., Yao, T., Li, P., & Yang, P. (2019) · Hepatology · doi:10.1002/hep.30960 · Cited by 40
“(11,12) HDAC inhibitors have wide applications in cancer therapy.(13,14) To fully understand the functional role of each individual HDAC gene in HCC/ peritumor, we screened the expression patterns in several gene chip databases and identified HDAC6 as the most significant deacetylase.”
MethodBeyond the M‐ CSF receptor – novel therapeutic targets in tumor‐associated macrophages
Bonelli, S., Geeraerts, X., Bolli, E., Keirsse, J., Kiss, M., Antunes, A. R. P., Damme, H. V., Vlaminck, K. D., Movahedi, K., Laoui, D., et al. (2017) · FEBS Journal · doi:10.1111/febs.14202 · Cited by 43
Mechanisms of resistance to estrogen receptor modulators in ER+/HER2− advanced breast cancer
Zhang, J., Wang, Q., Wang, Q., Cao, J., Sun, J., & Zhu, Z. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03281-4 · Cited by 42
Mechanisms of Resistance to Checkpoint Blockade Therapy
Shi, H., Lan, J., & Yang, J. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-3266-5_5 · Cited by 40
Trained immunity inducers in cancer immunotherapy
Sui, Y., & Berzofsky, J. A. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1427443 · Cited by 44
Diamonds in the Rough: Harnessing Tumor-Associated Myeloid Cells for Cancer Therapy
Clappaert, E. J., Murgaski, A., Damme, H. V., Kiss, M., & Laoui, D. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02250 · Cited by 41
“Finally, the inhibition of a group of histone deacetylases, HDAC class IIa, by a specific inhibitor, TMP195, reduced tumor burden and pulmonary metastasis by modulating the TAM phenotype in the murine MMTV-PyMT breast cancer model, and enhanced chemo-and T-cell checkpoint blockade therapy (53).”
BackgroundYou, H., Baluszek, S., & Kaminska, B. (2020) · Theranostics · doi:10.7150/thno.40783 · Cited by 40
“When combined with chemotherapy regimens or T-cell checkpoint blockade, TMP195 treatment significantly reduced tumor burden [118].”
BackgroundMoreno, C. M., Haynie, C., Cheever, A., & Weber, K. S. (2022) · Biomedicines · doi:10.3390/biomedicines10071493 · Cited by 41
Liu, Y., Sun, Q., Zhang, C., Ding, M., Wang, C., Zheng, Q., Ma, Z., Xu, H., Zhou, G., Wang, X., et al. (2023) · iScience · doi:10.1016/j.isci.2023.107376 · Cited by 40
“In recent years, more and more studies have shown that STING regulates the immune response of macrophages to tumors, thereby affecting the growth and metastasis of tumors.(26,27) However, its specific function andmechanism in colorectal cancer metastasis are still to be resolved.”
BackgroundImmunotherapy in Ovarian Cancer
Wang, W., Liu, J. R., & Zou, W. (2019) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2019.02.002 · Cited by 43
Bringing Macrophages to the Frontline against Cancer: Current Immunotherapies Targeting Macrophages
Reis-Sobreiro, M., da Mota, A. T., Jardim, C., & Serre, K. (2021) · Cells · doi:10.3390/cells10092364 · Cited by 45
“avenue of investigation to program macrophages and histone acetyl deacetylase (HDAC) inhibitors, which cause changes in the transcriptional profile of the macrophages, was shown to limit tumor growth [314].”
BackgroundAntibody-lectin chimeras for glyco-immune checkpoint blockade
Stark, J. C., Gray, M. A., Ibarlucea-Benitez, I., Lustig, M., Bond, A., Cho, B., Govil, I., Luu, T., Priestley, M. J., Veth, T. S., et al. (2025) · Nature Biotechnology · doi:10.1038/s41587-025-02884-6 · Cited by 54
Li, Y., He, P., Chen, Y., Hu, J., Deng, B., Liu, C., Yu, B., & Dong, W. (2024) · Scientific Reports · doi:10.1038/s41598-024-63993-x · Cited by 46
Ning, Y., Ding, J., Sun, X. Y., Xie, Y., Su, M., Ma, C., Pan, J., Chen, J., Jiang, H., & Qi, C. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000529 · Cited by 37
Li, X., Yang, Y., Huang, Q., Deng, Y., Guo, F., Wang, G., & Liu, M. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.738373 · Cited by 39
Metabolism in tumor-associated macrophages
Li, J., DeNicola, G. M., & Ruffell, B. (2022) · International review of cytology · doi:10.1016/bs.ircmb.2022.01.004 · Cited by 39
Sei, S., Ahadova, A., Keskin, D. B., Bohaumilitzky, L., Gebert, J. F., Doeberitz, M. V. K., Lipkin, S. M., & Kloor, M. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1147590 · Cited by 38
An Ex Vivo 3D Tumor Microenvironment-Mimicry Culture to Study TAM Modulation of Cancer Immunotherapy
Li, Y.-R., Yu, Y., Kramer, A. B., Hon, R., Wilson, M., Brown, J., & Yang, L. (2022) · Cells · doi:10.3390/cells11091583 · Cited by 40
“We envision that the ex vivo 3D TME-mimicry culture presented here could be further applied to evaluating the therapeutic effects of a large array of molecule-based immunotherapies targeting TAMs including CCL2/CCR2 inhibition [54], CSF1/CSF1R blockade [22], CD40 agonists [55], HDAC inhibition [56], and PI3Kγ inhibiti…”
BackgroundTumor-Associated Macrophage Targeting of Nanomedicines in Cancer Therapy
Kang, X., Huang, Y., Wang, H., Jadhav, S., Yue, Z., Tiwari, A. K., & Babu, R. J. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics16010061 · Cited by 38
“Through the Src homology region, two domain-containing phosphatases (SHP-1 and/or SHP-2) mediated inhibitory signals were generated, suppressing innate immune cells’ reaction against tumor cells [155,156].”
BackgroundGuo, R., Wang, R., Zhang, W., Li, Y., Wang, Y., Wang, H., Li, X., & Song, J. (2025) · Cancer Control · doi:10.1177/10732748251316604 · Cited by 43
“129 Epigenetic reprogramming of macrophages signi fi cantly affects their function in the tumour microenvironment through the regulation of m6A modi fi cations and associated signalling pathways.”
At the bench: Engineering the next generation of cancer vaccines
Shae, D., Baljon, J. J., Wehbe, M., Becker, K. W., Sheehy, T. L., & Wilson, J. T. (2019) · Journal of Leukocyte Biology · doi:10.1002/jlb.5bt0119-016r · Cited by 34
Metabolic programming of tumor associated macrophages in the context of cancer treatment
Crezee, T., Rabold, K., de Jong, L., Jaeger, M., & Netea-Maier, R. T. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-1114 · Cited by 33
“Combining TMP195 with chemotherapy regimens or T-cell checkpoint blockade significantly enhanced the durability of tumor reduction in different studies (96), underscoring a potential role of macrophages in treatment duration.”
BackgroundQiao, T., Yang, W., He, X., Song, P., Chen, X., Liu, R., Xiao, J., Yang, X., Li, M., Gao, Y., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05626-1 · Cited by 35
“CD11b F4/80 TAMs contribute to tumor vascularization within CRLM We next treated mice with a Class IIa Histone deacetylase (HDAC) inhibitor TMP195 which acted on macrophage polarization towards an M1-like phenotype in vivo [29].”
BackgroundMethodInfluentialYang, F., Hu, T., Liu, J.-Q., Yu, X., & Ma, L. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114920 · Cited by 32
Song, C. L., Gao, D., Yuan, T., Chen, Y., Liu, L., Chen, X., & Jiang, Y. (2019) · Chinese Chemical Letters · doi:10.1016/j.cclet.2019.02.017 · Cited by 34
Glass, E. B., Masjedi, S., Dudzinski, S. O., Wilson, A. J., Duvall, C. L., Yull, F. E., & Giorgio, T. D. (2019) · ACS Omega · doi:10.1021/acsomega.9b01465 · Cited by 33
Wang, C., Li, Y., Chen, H., Huang, K., Liu, X., Qiu, M., Liu, Y., Yang, Y., & Yang, J. (2018) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.247130 · Cited by 37
“Polarization of TAMs is a novel strategy for vascular normalization and antitumor immunity (Huang et al., 2011).”
BackgroundMalik, S., Sureka, N., Ahuja, S., Aden, D., Zaheer, S., & Zaheer, S. (2024) · Cell Biology International · doi:10.1002/cbin.12226 · Cited by 36
“In a mouse model of breast cancer, the administration of TMP195 induced the recruitment and differentiation of immunostimulatory M1 TAMs, resulting in a reduction in tumor size (Guerriero et al., 2017; Lobera et al., 2013).”
Ye, J., Zhong, S., Wan, H., Guo, X., Yao, X., Liu, Q., Chen, L., Wang, J., & Xiao, S. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00796-2 · Cited by 34
“Studies of HDAC7 in peripheral immune cells have shown that inhibiting HDAC7 can enhance the phagocytic ability of macrophages, leading to increased anti-tumor activity [30] [32].”
Metastatic Latency, a Veiled Threat
Kim, K., Marquez-Palencia, M., & Malladi, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01836 · Cited by 33
“HDAC inhibition reverts the pro-tumorigenic phenotype of tumor associated macrophages, recruits anti-tumor phagocytic macrophages and stimulates the adaptive immune response (127).”
BackgroundCancer-Homing CAR-T Cells and Endogenous Immune Population Dynamics
Guerra, E., Pietro, R. D., Basile, M., Trerotola, M., & Alberti, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010405 · Cited by 32
“Broader approaches to TAM reprogramming include inhibition of DICER, a pivotal enzyme for microRNA synthesis [125], and inhibitors of histone deacetylase [126].”
MethodEpigenetic regulation of breast cancer metastasis
Thakur, C., Qiu, Y., Pawar, A. S., & Chen, F. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10146-7 · Cited by 38
“Also, inhibition of class IIa HDAC decreased breast tumors and metastasis via anti-tumor immune cells such as macrophages [292].”
An Overview of HDAC Inhibitors and their Synthetic Routes
Peng, X., Liao, G., Sun, P., Yu, Z., & Chen, J. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190227221507 · Cited by 31
Qiu, J., Sharma, S., Rollins, R. A., & Paul, T. A. (2020) · Future Medicinal Chemistry · doi:10.4155/fmc-2020-0072 · Cited by 31
Ghiboub, M., Elfiky, A. M. I., de Winther, M. P. J., Harker, N. R., Tough, D. F., & de Jonge, W. J. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11050336 · Cited by 28
“TMP195 exhibited a potent effect on monocyte and macrophage activation in vitro, reducing CCL2 protein secretion and increasing the production of CCL1 by monocyte-derived macrophages and modifying human monocyte responses to the colony-stimulating factors CSF-1 and CSF-2 in vitro [55].”
BackgroundNishide, S., Matsunaga, S., Shiota, M., Yamaguchi, T., Kitajima, S., Maekawa, Y., Takeda, N., Tomura, M., Uchida, J., Miura, K., et al. (2019) · iScience · doi:10.1016/j.isci.2019.08.033 · Cited by 31
“On the other hand, other studies have reported that vessel normalization alters the TME and activates anti-tumor immunity; therefore, vascular normalization is emerging as a strategy for enhancing cancer therapy (Quail and Joyce, 2013; Henze and Mazzone, 2016; Park et al., 2016).”
BackgroundTu, B., He, Y., Chen, B., Wang, Y., Gao, Y., Shi, M., Liu, T., Asrorov, A. M., & Huang, Y. (2020) · Biomaterials Science · doi:10.1039/d0bm01516d · Cited by 28
HDAC7 Inhibition by Phenacetyl and Phenylbenzoyl Hydroxamates
Mak, J. Y. W., Wu, K., Gupta, P. K., Barbero, S., McLaughlin, M. G., Lucke, A. J., Tng, J., Lim, J., Loh, Z., Sweet, M. J., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01967 · Cited by 33
Liu, Y., Shang, W., Liu, H., Hui, H., Wu, J., Zhang, W., Gao, P., Guo, K., Guo, Y., & Tian, J. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01248-5 · Cited by 32
“In this regard, selective M2-to-M1 macrophage repolarization has drawn significant attention for alleviating immunosuppression and improving antitumor responses [19, 20].”
BackgroundRecent Synthetic Approaches towards Small Molecule Reactivators of p53
Silva, J. L., Lima, C. G. S., Rangel, L. P., Ferretti, G. D. S., Pauli, F. P., Ribeiro, R. C. B., Silva, T. B., da Silva, F. D. C., & Ferreira, V. F. (2020) · Biomolecules · doi:10.3390/biom10040635 · Cited by 31
Overview of the microbiota in the gut-liver axis in viral B and C hepatitis
Neag, M. A., Mitre, A. O., Cătinean, A., & Buzoianu, A. D. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i43.7446 · Cited by 31
Weber, J. S., Levinson, B. A., Laino, A. S., Pavlick, A. C., & Woods, D. M. (2022) · Melanoma Research · doi:10.1097/cmr.0000000000000818 · Cited by 32
Yen, J.-H., Huang, W.-C., Lin, S.-C., Huang, Y., Chio, W.-T., Tsay, G. J., Hung, M., & Huang, S. (2022) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2022.06.008 · Cited by 28
Cai, W., Sun, T., Qiu, C., Sheng, H., Chen, R., Xie, C., Kou, L., & Yao, Q. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02925-3 · Cited by 30
“Epigenetic regulation by inhibiting class IIa histone deacetylases (HDACs) is a promising method for utilizing the anti-tumor potential of macrophages, as it can repo-larize M2-TAMs into M1-TAMs by modifying their epigenetic profile [111].”
MethodAddressing Resistance to Immune Checkpoint Inhibitor Therapy: An Urgent Unmet Need
Hu‐Lieskovan, S., Malouf, G. G., Jacobs, I. A., Chou, J., Liu, L., & Johnson, M. L. (2021) · Future Oncology · doi:10.2217/fon-2020-0967 · Cited by 32
Epigenetic Regulation of Cancer Immune Cells
Patino, D. M. A., Radhakrishnan, V., Suvilesh, K. N., Manjunath, Y., Li, G., Kimchi, E. T., Staveley-O’Carroll, K. F., Warren, W. C., Kaifi, J. T., & Mitchem, J. B. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.06.022 · Cited by 28
Upadhyay, N., Tilekar, K. N., Safuan, S., Kumar, A. P., Schweipert, M., Meyer‐Almes, F., & Ramaa, C. S. (2021) · RSC Medicinal Chemistry · doi:10.1039/d1md00125f · Cited by 30
Dong, Y., Zhang, S., Gao, X., Yin, D., Wang, T., Li, Z., Wan, Z., Wei, M., Luo, Y., Yang, G., et al. (2021) · Bioactive Materials · doi:10.1016/j.bioactmat.2021.02.008 · Cited by 39
“For example, studies have shown that antiCD47 antibodies [27,28], toll-like receptor agonist [29], anti-CD40 antibodies [30], histone deacetylase inhibitors [31], anti-MARCO antibody therapy [32], PI3Kγ inhibitors [33] and inhibition of related miRNAs [34] are intensively studied strategies for TAMs repolarization [16…”
BackgroundZhu, K., Xia, Y., Tian, X., He, Y., Zhou, J., Han, R., Guo, H., Song, T., Chen, L., & Tian, X. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1271381 · Cited by 28
“Histone deacetylase (HDAC) is a large class of epigenetic metalloenzyme that are involved in gene transcription and regulation; proliferation, differentiation, migration, death and angiogenesis (Guerriero et al., 2017).”
BackgroundThe solid tumor microenvironment and related targeting strategies: a concise review
Wang, Y., Zhou, H., Ju, S., Dong, X., & Zheng, C. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1563858 · Cited by 219
Epigenetic Modifiers: Anti-Neoplastic Drugs With Immunomodulating Potential
Maes, K., Mondino, A., Lasarte, J. J., Agirre, X., Vanderkerken, K., Prósper, F., & Breckpot, K. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.652160 · Cited by 26
Cai, Z., LIM, D. J., Liu, G., Chen, C., Jin, L., Duan, W., Ding, C., Sun, Q., Peng, J., Dong, C., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.646384 · Cited by 33
“In recent years, some scholars have reported that a histone deacetylase inhibitor (HDACi), TMP195 can switch the major macrophage type in tumors from TAMs to the high phagocytic macrophages in mice mammary tumors (27).”
BackgroundMethodResultInfluentialA dual macrophage polarizer conjugate for synergistic melanoma therapy
Sallam, M. A., Shields, C. W., Prakash, S., Kim, J., Pan, D. C., & Mitragotri, S. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.05.033 · Cited by 24
Advances in the Design and Development of PROTAC-mediated HDAC Degradation
Rodrigues, D. A., Roe, A. J., Griffith, D. M., & Chonghaile, T. N. (2021) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026621666211015092047 · Cited by 29
Gupta, K. D., Ramnath, D., von Pein, J. B., Curson, J. E. B., Wang, Y., Abrol, R., Kakkanat, A., Moradi, S. V., Gunther, K. S., Murthy, A. M. V., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2212813120 · Cited by 30
Trifluoromethyloxadiazoles: inhibitors of histone deacetylases for control of Asian soybean rust
Winter, C., Fehr, M., Craig, I. R., Grammenos, W., Wiebe, C., Terteryan‐Seiser, V., Rudolf, G. C., Mentzel, T., & Palomar, M. A. Q. (2020) · Pest Management Science · doi:10.1002/ps.5874 · Cited by 25
Lin, X., Fang, Y., Jin, X., Zhang, M., & Shi, K. (2021) · ACS Applied Bio Materials · doi:10.1021/acsabm.1c00461 · Cited by 25
Mechanobiological Strategies to Augment Cancer Treatment
Kumari, A., Veena, S., Luha, R., & Tijore, A. (2023) · ACS Omega · doi:10.1021/acsomega.3c06451 · Cited by 24
CMTM3 suppresses chordoma progress through EGFR/STAT3 regulated EMT and TP53 signaling pathway
Yuan, W., Wei, F., Ouyang, H., Ren, X., Hang, J., Mo, X., & Liu, Z. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02159-5 · Cited by 27
“Tumors were measured along two orthogonal axes (a = length, b = width) and tumor volume was calculated using the following formula: volume = a × b2/2 [40].”
Chauchet, X., Cons, L., Chatel, L., Daubeuf, B., Didelot, G., Moine, V., Chollet, D., Malinge, P., Pontini, G., Masternak, K., et al. (2022) · Experimental Hematology and Oncology · doi:10.1186/s40164-022-00279-w · Cited by 26
Liang, Y., He, J., Chen, X., Yin, L., Yuan, Q., Zeng, Q., Zu, X., & Shen, Y. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.86039 · Cited by 30
Sun, P., Zhang, S., Maksim, S., Yao, Y., Liu, H., & Du, J. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190619143706 · Cited by 24
Luckhurst, C. A., Maillard, M. C., & Dominguez, C. (2018) · Worldwide Protein Data Bank · doi:10.2210/pdb6fyz/pdb · Cited by 25
Class IIa HDAC4 and HDAC7 cooperatively regulate gene transcription in Th17 cell differentiation
Cheung, K. L., Zhao, L., Sharma, R., Ghosh, A., Appiah, M. G., Sun, Y., Jaganathan, A., Hu, Y., Lejeune, A., Xu, F., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2312111121 · Cited by 26
Lorestani, P., Dashti, M., Nejati, N., Habibi, M. A., Askari, M., Robat-Jazi, B., Ahmadpour, S., & Tavakolpour, S. (2024) · Discover Oncology · doi:10.1007/s12672-024-01256-x · Cited by 27
“In preclinical cancer models, this reprogramming has been demonstrated to improve the effectiveness of immunotherapy and chemotherapy [83, 84].”
BackgroundAdler, K. A., Molina, P. E., & Simon, L. (2019) · Physiological Genomics · doi:10.1152/physiolgenomics.00043.2019 · Cited by 24
Isazadeh, A., Hajazimian, S., Garshasbi, H., Shadman, B., Baghbanzadeh, A., Chavoshi, R., Taefehshokr, S., Jadid, M. F. S., Hajiasgharzadeh, K., & Baradaran, B. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29905 · Cited by 25
van den Bijgaart, R. J. E., Kroesen, M., Brok, I. C., Reijnen, D., Wassink, M., Boon, L., Hoogerbrugge, P. M., & Adema, G. J. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1817653 · Cited by 27
“Thereby, TMP195 reduced tumor growth and pulmonary metastases in a preclinical breast cancer model.(29) Further research is needed to unravel the precise mechanisms underlying macrophage reprogramming and recruitment after HDAC inhibition.”
BackgroundNaicker, S. D., Feerick, C. L., Lynch, K., Swan, D., McEllistrim, C., Henderson, R. B., Leonard, N. A., Treacy, O., Natoni, A., Rigalou, A., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2020.1859263 · Cited by 23
Pérez‐Díez, A., Liu, X., & Matzinger, P. (2022) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0052 · Cited by 23
“Previous studies have shown that it is possible to obtain a partial phenotype reversal in ex vivo purified TAMs by delivering IL12 intratumorally (13), by stimulating with anti-CD40 antibodies (14) or by treatment with a class IIa histone deacetylase inhibitor (15).”
BackgroundTargeting tumor-associated macrophages for cancer immunotherapy
Cao, X., Lai, S. W. T., Chen, S., Wang, S., & Feng, M. (2022) · International review of cytology · doi:10.1016/bs.ircmb.2022.02.002 · Cited by 28
The ‘Danse Macabre’—Neutrophils the Interactive Partner Affecting Oral Cancer Outcomes
Hadjigol, S., Shah, B. A., & O’brien-simpson, N. M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.894021 · Cited by 26
Research progress in tumor targeted immunotherapy
Fang, Y., Yu, A., Ye, L., & Zhai, G. (2021) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2021.1882992 · Cited by 25
“Combining TMP195 with chemotherapy (carboplatin and paclitaxel) and T-cell checkpoint blockade (anti-PD-1 antibodies) could significantly enhance the anti-tumor effects [31].”
BackgroundMechanisms of tumor-associated macrophages in breast cancer and treatment strategy
Jin, H., Meng, X., & Feng, J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1560393 · Cited by 35
Cancer immune resistance: can theories converge?
Lu, R. O., Turan, T., Samayoa, J. A., & Marincola, F. M. (2017) · Emerging Topics in Life Sciences · doi:10.1042/etls20170060 · Cited by 22
Zhang, W., Shen, H.-R., Zhang, Y., Wang, W., Hu, S., Zou, D., & Zhou, D. (2019) · Cancer Medicine · doi:10.1002/cam4.2097 · Cited by 24
Zhu, W., Wang, C., Xue, L., Liu, L., Xiao-hong, Y., Liu, Z., Zhang, S., & Luo, D. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109352 · Cited by 22
Wu, J., Li, J.-X., Shu, N., Duan, Q.-J., Tong, Q., Zhang, J., Huang, Y., Yang, S., Zhao, Z., & Du, J. (2021) · Nano Research · doi:10.1007/s12274-021-3510-0 · Cited by 23
Tumor-Associated Macrophages: New Horizons for Pituitary Adenoma Researches
Han, C., Lin, S., Lu, X., Li, X., & Wu, Z. B. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.785050 · Cited by 28
“In other solid tumors, macrophage reprogramming therapy includes the use of anti-CD47 antibodies, anti-CD40 antibodies, Toll-like receptor (TLR) agonists, histone deacetylase (HDAC) inhibitors and PI3K inhibitors (76, 77, 81, 82).”
BackgroundTransforming cancer cells for long-term living with cancer: An inspiring new approach
Jiang, M., Gu, D.-N., Liu, F.-R., Lin, C.-J., & Tian, L. (2023) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2023.02.03 · Cited by 22
Metadata
- Authors
- Guerriero, J. L., Sotayo, A., Ponichtera, H. E., Castrillon, J. A., Pourzia, A. L., Schad, S., Johnson, S. F., Carrasco, R. D., Lazo, S., Bronson, R. T., Davis, S. P., Lobera, M., Nolan, M. A., & Letai, A.
- Affiliations
- Dana-Farber Cancer Institute (US)
- Brigham and Women's Hospital (US)
- Harvard University (US)
- GlaxoSmithKline (United States) (US)
- Corresponding author
- Nolan, Michael A.
- Letai, Anthony
- ORCID
- Venue
- Nature
- Published
- 2017-03
- Volume
- 543
- Issue
- 7645
- Pages
- 428-432
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC8170529
- OpenAlex
- W2591627715
- Cited by
- 558
- References
- 35
- Citations by year
- 2026: 35 · 2025: 51 · 2024: 51 · 2023: 63 · 2022: 74 · 2021: 94 · 2020: 68 · 2019: 63 · 2018: 33 · 2017: 25
- FWCI
- 23.51
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Cancer Institute (R01CA205967, F32CA180733)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Keywords
- breast cancer, tumour-associated macrophages, antitumor immunity, tumor microenvironment, lung metastasis, chemotherapy synergy, T cell checkpoint blockade, CSF-1
- MeSH terms
- Animals, Benzamides, Breast Neoplasms, Cell Differentiation, Disease Models, Animal, Drug Synergism, Female, Humans, Lung Neoplasms, Macrophage Activation, Macrophages, Oxadiazoles, Phagocytosis, Cell Line, Tumor, Tumor Burden, Mice, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.